en · de · es · pt
melanotan-2-notes.peptides1004.com › Blog › Melanotan-2 Identity And Regulatory Status — Hands-On Walkthrough

Melanotan-2 Identity And Regulatory Status — Hands-On Walkthrough

By Editorial Desk · published 2025-10-23 · last reviewed 2025-11-27 · Blog

melanocortin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.

Melanotan-2 Identity And Regulatory Status

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Origins and Research Status

Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideAnalogue of alpha-melanocyte-stimulating hormone
Common synonymsMT-II; melanotan 2No internationally accepted non-proprietary name
Typical presentationLyophilised powder in a sealed vialOften supplied alongside a separate diluent
Regulatory statusUnapproved therapeutic substanceCustoms seizure reported in several jurisdictions
Reported route in useSubcutaneous injectionSelf-administered outside clinical settings

Melanotan II Background and Mechanism

Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.

Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.

Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.

Related pages on this site

Melanotan-2 Structure and Receptor Pharmacology

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Supporting material

== Treatment == Due to the deterministic nature of moist desquamation, once symptoms occur the condition itself can not be reversed and a patient must wait for the condition to subside. Management of these partial-thickness wounds has been influenced by the Winter principle of moist wound healing, which suggests that wounds heal more rapidly in a moist environment. Hydrocolloid dressings applied directly to these wounds prevent the evaporation of moisture from the exposed dermis and create a moist environment at the wound site that promotes cell migration. As additional radiation exposure may either exacerbate or cause the re-occurrence of moist dequamation, patients are advised to use sunscreen over the irradiated area after completion of treatment.

There are numerous factors to consider when evaluating health hazards in seafood. These concerns include marine toxins, microbes, foodborne illness, radionuclide contamination, and man-made pollutants. Shellfish are among the more common food allergens. Most of these dangers can be mitigated or avoided with accurate knowledge of when and where seafood is caught. However, consumers have limited access to relevant and actionable information in this regard and the seafood industry's systemic problems with mislabelling make decisions about what is safe even more fraught. Ciguatera fish poisoning (CFP) is an illness resulting from consuming toxins produced by dinoflagellates which bioaccumulate in the liver, roe, head, and intestines of reef fish. It is the most common disease associated with seafood consumption and poses the greatest risk to consumers. The population of plankton that produces these toxins varies significantly over time and location, as seen in red tides. Evaluating the risk of ciguatera in any given fish requires specific knowledge of its origin and life history, information that is often inaccurate or unavailable. While ciguatera is relatively widespread compared to other seafood-related health hazards (up to 50,000 people suffer from ciguatera every year), mortality is very low. Scombroid food poisoning, is also a seafood illness. It is typically caused by eating fish high in histamine from being stored or processed improperly.

In Italian, they are called pinoli (in the US, they are often called pignoli, but in Italy, pignolo is actually a word far more commonly used to describe a fussy, overly fastidious or extremely meticulous person) and are an essential component of Italian pesto sauce; the upsurge in the popularity of this sauce since the 1990s has increased the visibility of the nut in America, primarily on the West Coast. Torta della nonna (literally "granny's cake") is a generic Italian dish name that in most families indicates an old family recipe for any cake but often is used for a tart or a pie filled with custard, topped with pine nuts and optionally dusted with icing sugar. Pignoli cookies, an Italian American specialty confection (in Italy, these would be called biscotti ai pinoli), are made of almond flour formed into a dough similar to that of a macaroon and then topped with pine nuts. In the Catalan-speaking regions of Spain, a sweet called panellets is made of small marzipan balls covered with pine nuts, painted with egg, and lightly cooked. Pine nuts are also featured in the salade landaise of southwestern France. Nevada, or Great Basin, pine nut has a sweet fruity flavor and is promoted for its large size, sweet flavor, and ease of peeling.

Sources: en.wikipedia.org

Notes from published material

Jack Watson was born on May 2, 1939, in Casey, Iowa, to Jesse H. and Anne Watson. Jack grew up in a town of about 1,000 residents in northern Iowa, Nora Springs. His father was the area's school superintendent and he had one brother. After graduating from Nora Springs High School 1957, he went to Iowa State University, majoring in chemistry and taking part in the University’s Air Force ROTC program for four years which accounts for the four years he spent on active duty in California and Texas. Before serving his Air Force obligation, after graduation Iowa State with a degree in Chemical Technology in 1961, he went to graduate school at the Massachusetts Institute Technology (MIT). At MIT, Watson was a PhD candidate in the laboratory of Klaus Biemann, one of the most notable experts in organic mass spectrometry at the time. As soon as he graduated from MIT, Watson reported for duty in the United States Air Force in the San Francisco Bay area. A friend of his from high school, introduced Watson to Judith Sjoberg. Not long after that, they were married and moved to Brooks Air Base in San Antonio, Texas. After completing his tour of duty in the Air Force, Watson took a one-year postdoctoral position in Strasbourg France at the Institut de Chimie, Université de Strasbourg under the direction of Robert Wolf. During this time and through the licensing of the Watson-Biemann gas separator to Thomson-CSF, for use in a gas chromatograph-mass spectrometer they ware manufacturing at the time, Watson made everlasting ties to the French Mass Spectrometry community.

=== Jeff === Jeff, a blind monster in chapter seven, came from the idea of forcing the player to share space with a frightening entity in VR. The team created several versions, including a Combine robot, before settling on a horror-influenced creature. Valve forced players to do things they did not want but still found enjoyable, such as leading them to the realization that they had to release Jeff after trapping him. They also gave the player more opportunities to escape when Jeff caught them, as near-deaths were exciting and too many deaths proved frustrating. Combat sequences with other enemies, designed to demonstrate Jeff's strength, were removed as they distracted from the tension. The chapter contains more physics objects than the entirety of Half-Life 2, and was set in a distillery to explain the abundance of bottles the player can throw to distract Jeff. It includes alien spores that cause Alyx to cough, drawing Jeff's attention. After playtesters instinctively covered their mouths, the team implemented this into the design. This also added strategy, as players have to keep one hand free to carry a bottle. At the end of the chapter, the player traps Jeff in a trash compactor. Most playtesters chose to activate the compactor and crush him.

== Function == Exercise causes increased expression in muscle of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1alpha), which is involved in adaptation to exercise. In mice, this causes production of the FNDC5 protein which is cleaved to give a new product irisin. Due to its production through a mechanism initiated by muscular contraction, irisin has been classified as a myokine.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II approved for medical use?

No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.

Where did melanotan II originate?

It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.

Why is purity a concern for unapproved peptides?

Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.

What is melanotan II?

It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.

Network